Please login to the form below
Chimerix
This page shows the latest Chimerix news and features for those working in and with pharma, biotech and healthcare.
Merck says drug for CMV in transplant patients hits targets
The company's good news comes after another CMV drug developer - Chimerix - reported that its brincidofovir CMV candidate failed a pair of pivotal trials.
Latest news
-
Chimerix hit as lead drug brincidofovir flunks trial
Patients in the brincidofovir arm also showed an increase in mortality compared to the control arm, but the increase was not statistically significant, according to Chimerix. ... Both GVHD and use of corticosteroids are risk factors for 'late' CMV
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Pharma deals during July 2012
Anti-infective deals. A similar size to the Genmab deal at $168m is the agreement between Chimerix, a US based private company developing antiviral therapies and Merck &Co. ... 178. Chimerix / Merck &Co. Licence. Lipid antiviral conjugate in phase 1 for
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Former Glaxo CEO Ernest Mario to chair Chimerix
Chimerix has appointed pharma veteran and former CEO of Glaxo Holdings Dr Ernest Mario as the company's new chairman. ... Dr Mario replaces Dr James Niedel, who will remain as a member of the board at Chimerix.
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Apex.co.uk Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
